Sheet 1	of 1			9888	A Comment					
INFORM	MATION DISCHOSURE	, ATTY,	. ATTY, DOCKET NO. OCT 2 4 2009 BERIAL NO.							
	CITATION				5/ 10/564,637	· · · · · · · · · · · · · · · · · · ·				
		APPLIC	CANT	TRADENAM						
		_		··		·				
(Use	several sheets if necessary)	FILING	FILING DATE		GROUP					
		Augı	August 10, 2006		1625					
			J.S. PATENT DO	DCUMENTS	<u> </u>		- FILING	DATE		
*EXAMINER INITIAL				NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
		FOF	REIGN PATENT	DOCUMENTS						
	DOCUMENT	DATE		COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO		
			<u> </u>							
	OTHER DOCL	L JMENTS (ii	ncludina Autho	r. Title. Date. Pe	rtinent pages, e	tc.)				
	Li et al, "Three Inhibito	rs of Type 1	Human Immunod	eficiency Virus Lo	ng Terminal", F	Proc. Natl. A	cad. Sci.	USA,		
	Vol. 99, pp. 1839-1842, March, 1993. Garcia-Carbonero et al, "Current Perspectives on the Clinical Experience, Pharmacology", Clinical Cancer Research,									
	Vol. 8, 641-661, March 2002.									
	Dallavalle et al, "Perspectives in Camptothecin Development", Expert Opinion Ther. Patents (2002) 12(6) 837; XP-002251117.									
	Lesueur-Ginot et al, "Homocamptothecin, an E-Ring Modified Camptothecin", Cancer Research 59, 2939-2943, June 15, 1999.									
	Vladu et al, "7- and 10-Substituted Camptothecins: Dependence of Topoisomerase", Molecular Pharmacology, 57:243-251 (2000).									
	Dallavalle et al, "Novel	7-Oxyimino	methyl Derivative	s", J. Med. Che	m. 2001, 44, 3264-	-3274.				
	Kantarjian et al, "Phase 1146-1151.									
	Kaufmann et al, "Topoi 530.									
	Lichtman et al, "Chemo 556.									
	Bodley et al, "Molecular and Cytotoxic Effects", Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 3726-3730, April 1995.									
	Priel et al, "The Topoiso						5410 541			
	Lavergne et al, "Homoc	amptothecin	s: Synthesis and	Antitumor Activity	", J. Med. Chen	n. 1998, 41, 3	0410-541	9.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

Examiner		Date Considered								
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial a this form with next communication to application.										